NEW YORK (GenomeWeb) – Having earlier this month unveiled its plan to
merge with hepatitis B therapeutics firm OnCore Biopharma, Tekmira
Pharmaceuticals has provided a few details about its drug-development
plans going forward in a recent filing with the US Securities and
Exchange Commission.
Going forward, Tekmira aims to make its
siRNA-based HBV therapy TKM-HBV the foundation of a treatment regimen
that will also include one or two other drugs from OnCore's pipeline of
preclinical candidates, it said in the SEC filing.
This
combination strategy, Tekmira noted, is the same one behind the
development of the highly effective hepatitis C therapy Harvoni, which
combines the HCV drug sofosbuvir that was developed by OnCore founders
while at Pharmasset and Gilead Sciences' ledipasvir. Gilead acquired
Pharmasset for $11 billion in 2011.
Read more...Labels: Tekmira, TKM-HBV